Portfolio integrates mesenchymal stem cells, NK cell therapy and AI diagnostics via global licensing with Yike. Launching in Hong Kong, Singapore and China.Read More
Visionary Holdings (Nasdaq: GV) unveils 3-category stem cell anti-aging line across Asia
Related Posts
Add A Comment
